FR13C0035I2 - Nouveaux derives d'insuline - Google Patents

Nouveaux derives d'insuline

Info

Publication number
FR13C0035I2
FR13C0035I2 FR13C0035C FR13C0035C FR13C0035I2 FR 13C0035 I2 FR13C0035 I2 FR 13C0035I2 FR 13C0035 C FR13C0035 C FR 13C0035C FR 13C0035 C FR13C0035 C FR 13C0035C FR 13C0035 I2 FR13C0035 I2 FR 13C0035I2
Authority
FR
France
Prior art keywords
insulin derivatives
new insulin
new
derivatives
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0035C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of FR13C0035I1 publication Critical patent/FR13C0035I1/fr
Application granted granted Critical
Publication of FR13C0035I2 publication Critical patent/FR13C0035I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR13C0035C 2003-08-05 2013-07-04 Nouveaux derives d'insuline Active FR13C0035I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (2)

Publication Number Publication Date
FR13C0035I1 FR13C0035I1 (enrdf_load_html_response) 2013-08-09
FR13C0035I2 true FR13C0035I2 (fr) 2014-03-07

Family

ID=34117520

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0035C Active FR13C0035I2 (fr) 2003-08-05 2013-07-04 Nouveaux derives d'insuline
FR13C0038C Active FR13C0038I1 (fr) 2003-08-05 2013-07-05 Nouveaux derives d'insuline

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR13C0038C Active FR13C0038I1 (fr) 2003-08-05 2013-07-05 Nouveaux derives d'insuline

Country Status (18)

Country Link
US (3) US7615532B2 (enrdf_load_html_response)
EP (3) EP2264065B1 (enrdf_load_html_response)
JP (1) JP4463814B2 (enrdf_load_html_response)
KR (1) KR101159559B1 (enrdf_load_html_response)
AU (2) AU2004261353B2 (enrdf_load_html_response)
BE (2) BE2013C035I2 (enrdf_load_html_response)
BR (1) BRPI0413276B8 (enrdf_load_html_response)
CA (1) CA2531988C (enrdf_load_html_response)
CY (5) CY1113850T1 (enrdf_load_html_response)
FR (2) FR13C0035I2 (enrdf_load_html_response)
HU (1) HUS1300033I1 (enrdf_load_html_response)
IL (1) IL172980A (enrdf_load_html_response)
LU (2) LU92213I2 (enrdf_load_html_response)
MX (1) MXPA06001283A (enrdf_load_html_response)
NO (5) NO340925B1 (enrdf_load_html_response)
PL (1) PL2107069T3 (enrdf_load_html_response)
RU (1) RU2518460C2 (enrdf_load_html_response)
WO (1) WO2005012347A2 (enrdf_load_html_response)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526957C (en) * 2003-07-25 2011-07-12 Conjuchem Inc. Long lasting insulin derivatives and methods thereof
MXPA06001283A (es) * 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
WO2006082204A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
ES2490243T3 (es) 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
PL1969004T3 (pl) * 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
ATE557037T1 (de) * 2006-02-27 2012-05-15 Novo Nordisk As Insulin derivate
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
RU2451029C2 (ru) * 2006-05-09 2012-05-20 Ново Нордиск А/С Производное инсулина
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
MX2009002999A (es) 2006-09-22 2009-04-01 Novo Nordisk As Analogos de insulina resistentes a proteasa.
EP2502618A3 (en) 2007-04-30 2012-10-03 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008145732A1 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
EP2164466A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
ES2548304T3 (es) * 2007-08-15 2015-10-15 Novo Nordisk A/S Análogos de la insulina que contienen una fracción acilo y alquilenglicol
US8962794B2 (en) 2007-08-15 2015-02-24 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
WO2009060071A1 (en) 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
CN101861333A (zh) 2007-11-16 2010-10-13 诺沃-诺迪斯克有限公司 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
PL2254906T3 (pl) 2008-03-18 2017-04-28 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
JP5591243B2 (ja) 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
EP2389190B1 (en) 2009-01-23 2018-09-19 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
CN102666579A (zh) 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 降钙素基因相关肽的衍生物
KR20120117013A (ko) * 2010-01-12 2012-10-23 노보 노르디스크 에이/에스 인슐린 펩티드의 경구 투여를 위한 약학적 조성물
CN102812039B (zh) 2010-02-16 2016-01-20 诺沃—诺迪斯克有限公司 缀合蛋白质
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación
CN107029212A (zh) 2010-05-10 2017-08-11 诺沃—诺迪斯克有限公司 用于制备胰岛素‑锌复合物的方法
EP2576612A4 (en) 2010-05-25 2014-07-09 Syngene Ltd INSULIN ANALOG
US8883722B2 (en) 2010-06-23 2014-11-11 Novo Nordisk A/S Human insulin containing additional disulfide bonds
JP5973427B2 (ja) 2010-06-23 2016-08-23 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン類似体
WO2011161125A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
JP6049625B2 (ja) * 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
CN103167878A (zh) 2010-10-27 2013-06-19 诺沃—诺迪斯克有限公司 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
US20130331320A1 (en) 2010-12-14 2013-12-12 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
WO2012110422A1 (en) 2011-02-15 2012-08-23 Novo Nordisk A/S Long-acting il-1 receptor antagonists
US20140031278A1 (en) * 2011-03-28 2014-01-30 Novo Nordisk A/S Novel Glucagon Analogues
US20140056953A1 (en) 2011-04-14 2014-02-27 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
BR112014013483A2 (pt) * 2011-12-15 2019-09-24 Jiangsu Hengrui Medicine Co análogo de insulina humana e derivado acilado do mesmo
JP2015502971A (ja) 2011-12-21 2015-01-29 ノヴォ ノルディスク アー／エス Ｎ末端修飾インスリン誘導体
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
CA2872083A1 (en) 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2908846A1 (en) 2012-10-17 2015-08-26 Novo Nordisk A/S Fatty acid acylated d-amino acids for oral peptide delivery
SG11201504215PA (en) 2012-12-21 2015-06-29 Sanofi Sa Functionalized exendin-4 derivatives
CN105188736A (zh) * 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
BR112016016321A2 (pt) 2014-02-18 2017-10-03 Novo Nordisk As Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
WO2017032795A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
WO2018024186A1 (zh) 2016-08-02 2018-02-08 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
JP7193455B2 (ja) 2016-11-28 2022-12-20 ノヴォ ノルディスク アー／エス 心血管状態におけるインスリンデグルデク
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
HRP20221324T1 (hr) 2016-12-16 2022-12-23 Novo Nordisk A/S Farmaceutski pripravci koji sadrže inzulin
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
CN111094572B (zh) 2018-02-09 2023-04-04 江苏恒瑞医药股份有限公司 一种密码子优化的人胰岛素类似物前体基因和信号肽基因
JP2021524464A (ja) 2018-05-24 2021-09-13 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． 組換えヒトインスリンまたはそのアナログの前駆体の調製方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2020002428A1 (en) 2018-06-26 2020-01-02 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN118598978A (zh) 2019-12-30 2024-09-06 甘李药业股份有限公司 胰岛素衍生物
CA3177905A1 (en) 2020-05-15 2021-11-18 Eli Lilly And Company Extended time action acylated insulin compounds
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
CN118574842A (zh) 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
DE69019534T2 (de) 1989-12-21 1995-09-21 Novonordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
DK45590D0 (enrdf_load_html_response) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
ES2185625T3 (es) 1991-12-20 2003-05-01 Novo Nordisk As Formulacion farmaceutica estabilizada que incluye hormona de crecimiento e histidina.
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
DE69428134T2 (de) 1993-09-17 2002-05-02 Novo Nordisk A/S, Bagsvaerd Acyliertes insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CA2215694A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
IL122910A (en) 1995-07-27 2002-05-23 Genentech Inc Stable isotonic protein formulation that has undergone lyophilization
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
ES2230607T3 (es) 1996-07-11 2005-05-01 Novo Nordisk A/S Metodo selectivo de acilacion.
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2218622T3 (es) * 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
IL131796A0 (en) * 1997-03-20 2001-03-19 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
DE69806582T2 (de) 1997-03-20 2003-02-13 Novo Nordisk A/S, Bagsvaerd Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
DE69806362T2 (de) 1997-03-20 2003-01-30 Novo Nordisk A/S, Bagsvaerd Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
SI0884053T1 (en) 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
DE69815877T2 (de) * 1997-10-24 2004-05-19 Novo Nordisk A/S Aggregate von menschlichen insulinderivaten
US6268335B1 (en) 1997-10-24 2001-07-31 Eli Lilly And Company Insoluble insulin compositions
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
DE69901726T2 (de) 1998-10-16 2002-12-19 Novo Nordisk As Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DK1154796T3 (da) * 1999-02-22 2007-09-24 Univ Connecticut Nye albuminfrie Faktor VIII-formuleringer
CA2370302A1 (en) 1999-04-27 2000-11-02 Benjamin Lee Hughes Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
PT1412384E (pt) 2001-06-28 2008-03-28 Novo Nordisk As Formulação estável de glp-1 modificado
KR20040070237A (ko) 2001-12-20 2004-08-06 일라이 릴리 앤드 캄파니 연장된 작용 시간을 갖는 인슐린 분자
US8003605B2 (en) * 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
ES2360182T3 (es) * 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
DE60317822D1 (de) 2002-10-29 2008-01-10 Alza Corp Stabilisierte feste polypeptidpartikel
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004069259A1 (ja) 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
PT1597367E (pt) 2003-02-19 2010-09-02 Scripps Research Inst Antigénio glicoproteína sima 135 expresso em células tumorais humanas metastáticas
US20110097385A1 (en) * 2003-03-04 2011-04-28 Ttdc Bio L.P. Delivery System for Drug and Cell Therapy
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
MXPA06001283A (es) * 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
KR101186851B1 (ko) 2003-08-05 2012-10-02 노보 노르디스크 에이/에스 신규의 인슐린 유도체
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
WO2005047508A1 (en) * 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
ATE554792T1 (de) 2003-12-23 2012-05-15 Pharmacia Corp Stabiles wachstumshormon-flüssigformulierung
EP2319500B1 (en) 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
EA012281B1 (ru) 2004-06-01 2009-08-28 Арес Трейдинг С.А. Способ стабилизации белков
ES2349472T3 (es) 2004-08-12 2011-01-03 Schering Corporation Formulación estable de interferón pegilado.
BRPI0514411B8 (pt) 2004-08-17 2021-05-25 Regeneron Pharma formulação, e, método de produzir uma formulação
US20090011976A1 (en) 2004-11-12 2009-01-08 Novo Nordisk A/S Stable Formulations Of Peptides
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
JP2008528509A (ja) 2005-01-21 2008-07-31 アルザ コーポレイション 少なくとも１つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤
WO2006082204A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
ATE557037T1 (de) * 2006-02-27 2012-05-15 Novo Nordisk As Insulin derivate
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
RU2451029C2 (ru) * 2006-05-09 2012-05-20 Ново Нордиск А/С Производное инсулина
ES2744384T3 (es) * 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
CN101861333A (zh) * 2007-11-16 2010-10-13 诺沃-诺迪斯克有限公司 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
CY2013029I2 (el) 2024-09-20
CY2013029PI2 (el) 2015-11-04
EP2264065B1 (en) 2017-03-08
RU2518460C2 (ru) 2014-06-10
LU92226I9 (enrdf_load_html_response) 2018-11-19
JP4463814B2 (ja) 2010-05-19
IL172980A (en) 2013-10-31
BRPI0413276A (pt) 2006-10-10
CY1113850T1 (el) 2015-11-04
US20060183668A1 (en) 2006-08-17
BRPI0413276B8 (pt) 2021-05-25
EP2107069A2 (en) 2009-10-07
AU2010200497B2 (en) 2014-10-23
CY2013027I1 (el) 2024-09-20
NO2018002I1 (no) 2018-01-11
AU2004261353B2 (en) 2009-12-10
CY2013029PI1 (el) 2015-11-04
BE2013C038I2 (enrdf_load_html_response) 2023-12-14
LU92226I2 (fr) 2015-04-29
NO20061026L (no) 2006-03-02
CY2013027I2 (el) 2024-09-20
NO2024004I1 (no) 2024-01-16
AU2010200497A1 (en) 2010-03-04
IL172980A0 (en) 2006-06-11
WO2005012347A3 (en) 2005-04-14
RU2008152033A (ru) 2010-07-10
US7615532B2 (en) 2009-11-10
NO340925B1 (no) 2017-07-17
KR101159559B1 (ko) 2012-06-26
CA2531988A1 (en) 2005-02-10
BRPI0413276B1 (pt) 2020-03-03
US8828923B2 (en) 2014-09-09
EP2107069B1 (en) 2013-01-16
LU92213I2 (fr) 2013-08-23
MXPA06001283A (es) 2006-04-11
EP1660531A2 (en) 2006-05-31
CY2013027PI2 (el) 2015-11-04
AU2004261353A1 (en) 2005-02-10
US20100009899A1 (en) 2010-01-14
NO2024003I1 (no) 2024-01-16
EP2264065A3 (en) 2011-07-27
CY2013029I1 (enrdf_load_html_response) 2024-09-20
BE2013C035I2 (enrdf_load_html_response) 2023-12-14
WO2005012347A2 (en) 2005-02-10
CA2531988C (en) 2016-06-28
FR13C0035I1 (enrdf_load_html_response) 2013-08-09
LU92213I9 (enrdf_load_html_response) 2018-11-19
KR20060132543A (ko) 2006-12-21
PL2107069T3 (pl) 2013-06-28
CY2013027PI1 (el) 2015-11-04
JP2007523881A (ja) 2007-08-23
NO2018003I1 (no) 2018-01-11
NO2018002I2 (no) 2018-08-20
EP2107069A3 (en) 2009-11-25
EP2264065A2 (en) 2010-12-22
HUS1300033I1 (hu) 2016-08-29
FR13C0038I1 (fr) 2013-08-09
US20140349925A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
FR13C0035I2 (fr) Nouveaux derives d'insuline
FR15C0062I2 (fr) Nouveaux derives d'oxazolidinone
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
MA27105A1 (fr) Nouveaux composes
MA26216A1 (fr) Nouveaux composes
EP1677822A4 (en) 4'-THIONUCLEOSIDES AND OLIGOMER COMPOUNDS
ATE499347T1 (de) Amidderivate
DE50304905D1 (de) Injektionspumpe
DK1652843T3 (da) Amidderivater
DE602004017533D1 (de) Reissverschluss
FR2851168B1 (fr) Site d'injection
EP1611147A4 (en) 6 "amino-6" -DEOXYGALACTOSYLCERAMIDE
MA28817B1 (fr) Nouveaux derives d'uree benzoyle
DE602004021207D1 (de) Reissverschluss
ATA15002002A (de) Spritzgiesseinrichtung
ATA6322002A (de) Spritzgiesseinrichtung
ATA5482002A (de) Spritzgiesseinrichtung
ATA4022002A (de) Spritzgiesseinrichtung
ATA4252002A (de) Spritzgiesseinrichtung
EP1635834A4 (en) NEW CONNECTIONS
FI20035069A0 (fi) Vetoketju
FR2852042B1 (fr) Piece d'aretier
ATA3962002A (de) Spritzgiesseinrichtung
FI20021817A7 (fi) Kanyyli
ATA3982002A (de) Spritzgiesseinrichtung